Dr. Clarence William Walker, PH.D Psychologist Medicare: Accepting Medicare Assignments Practice Location: 17 Ash Street, N.e, Post Office Box 92, New London, MN 56273 Phone: 320-354-4489 Fax: 320-354-4490 |
News Archive
Enzon Pharmaceuticals, Inc. today announced the results from the recent tender and increased conversion periods of the 4 percent convertible notes due in 2013. As a result of the sale of the specialty pharmaceutical business on January 29, 2010, the Company was required to offer to repurchase for cash any and all of its convertible notes at face value. This offer expired on March 5, 2010 and no notes were tendered.
A collaborative research effort by Australian and US scientists has led to the discovery of a promising new approach to treating some of the worst types of leukaemia, including an aggressive leukaemia that mostly affects babies.
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), announced that Pamela Pavco, Ph.D., Vice President of Pharmaceutical Development, will be presenting at the 3rd International Scar Club Meeting in Montpellier, France on March 26, 2010.
A low level of response (LR) to alcohol is one of several genetically influenced characteristics that may increase an individual's risk for heavy drinking and alcohol problems. A new study has confirmed key elements of a LR-based model of risk through examination of a large sample of adolescent boys and girls in the United Kingdom, moving beyond smaller U.S.-based samples and to younger subjects.
› Verified 1 days ago